JP2010531877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531877A5 JP2010531877A5 JP2010514837A JP2010514837A JP2010531877A5 JP 2010531877 A5 JP2010531877 A5 JP 2010531877A5 JP 2010514837 A JP2010514837 A JP 2010514837A JP 2010514837 A JP2010514837 A JP 2010514837A JP 2010531877 A5 JP2010531877 A5 JP 2010531877A5
- Authority
- JP
- Japan
- Prior art keywords
- picoplatin
- cancer
- solution
- item
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 55
- 229950005566 picoplatin Drugs 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 51
- 239000002552 dosage form Substances 0.000 claims description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 3
- -1 salt hydride ion Chemical class 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000006298 dechlorination reaction Methods 0.000 claims 1
- 239000002195 soluble material Substances 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 150000003841 chloride salts Chemical class 0.000 description 3
- 229910001504 inorganic chloride Inorganic materials 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94663907P | 2007-06-27 | 2007-06-27 | |
| US2738808P | 2008-02-08 | 2008-02-08 | |
| US5507108P | 2008-05-21 | 2008-05-21 | |
| PCT/US2008/008076 WO2009032034A2 (en) | 2007-06-27 | 2008-06-27 | Stabilized picoplatin dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531877A JP2010531877A (ja) | 2010-09-30 |
| JP2010531877A5 true JP2010531877A5 (enExample) | 2012-08-30 |
Family
ID=40429589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514837A Pending JP2010531877A (ja) | 2007-06-27 | 2008-06-27 | 安定化したピコプラチン投与形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100178328A1 (enExample) |
| EP (1) | EP2157864A4 (enExample) |
| JP (1) | JP2010531877A (enExample) |
| KR (1) | KR20100051797A (enExample) |
| CN (1) | CN101801198A (enExample) |
| AU (1) | AU2008295576A1 (enExample) |
| BR (1) | BRPI0811816A2 (enExample) |
| CA (1) | CA2691115A1 (enExample) |
| IL (2) | IL202743A0 (enExample) |
| MX (1) | MX2009013835A (enExample) |
| TW (1) | TW200916094A (enExample) |
| WO (1) | WO2009032034A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| WO2010132596A1 (en) * | 2009-05-12 | 2010-11-18 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| MX2009008487A (es) * | 2007-02-09 | 2010-01-15 | Poniard Pharmaceuticals Inc | Picoplatino encapsulado. |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
| US20110053879A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| EP2418955A4 (en) * | 2009-04-15 | 2012-11-21 | Poniard Pharmaceuticals Inc | ORBIOTIC ANTICANCER THERAPY BASED ON HIGH BIODISIBILITY PICOPLATIN |
| CN101804025B (zh) * | 2010-03-31 | 2011-09-21 | 昆明贵研药业有限公司 | 甲啶铂的一种水溶液注射剂 |
| CN102590385B (zh) * | 2012-02-14 | 2013-09-11 | 昆明贵研药业有限公司 | 一种甲啶铂及其杂质的检测方法 |
| AU2016260785B2 (en) * | 2015-05-13 | 2022-06-02 | Monopar Therapeutics Inc. | Clonidine and/or Clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy |
| CA3008749C (en) * | 2015-12-23 | 2024-01-02 | NuCana plc | Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin |
| CN106943343B (zh) * | 2016-01-06 | 2020-05-12 | 山东新时代药业有限公司 | 一种甲啶铂注射液及其制备方法 |
| CN107773538B (zh) * | 2016-08-27 | 2022-09-13 | 鲁南制药集团股份有限公司 | 稳定的甲啶铂无菌冻干粉末及其制备工艺 |
| CN117940164A (zh) * | 2022-04-26 | 2024-04-26 | 石药集团中奇制药技术（石家庄）有限公司 | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1432562A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB2060615B (en) * | 1979-08-23 | 1983-06-22 | Johnson Matthey Co Ltd | Platinum-amine complexes |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| GR75317B (enExample) * | 1980-09-03 | 1984-07-13 | Johnson Matthey Plc | |
| US4533502A (en) * | 1983-02-22 | 1985-08-06 | Rochon Fernande D | Platinum (II) compounds and their preparation |
| EP0167310B1 (en) * | 1984-06-27 | 1991-05-29 | Johnson Matthey Public Limited Company | Platinum co-ordination compounds |
| US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
| CA1327039C (en) * | 1986-12-18 | 1994-02-15 | Tetsushi Totani | Ammine-alicyclic amine-platinum complexes and antitumor agents |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB9105037D0 (en) * | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5244991A (en) * | 1991-10-15 | 1993-09-14 | Phillips Petroleum Company | Olefin polymerization process |
| MX9206577A (es) * | 1991-11-15 | 1993-05-01 | Smithkline Beecham Corp | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES |
| EP0672181B1 (en) * | 1992-04-01 | 2003-11-05 | The Johns Hopkins University School Of Medicine | Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor |
| SK279684B6 (sk) * | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
| US5624919A (en) * | 1993-09-14 | 1997-04-29 | The University Of Vermont And State Agricultural College | Trans platinum (IV) complexes |
| GB9408218D0 (en) * | 1994-04-26 | 1994-06-15 | Johnson Matthey Plc | Improvements in platinum complexes |
| WO1996001638A1 (en) * | 1994-07-11 | 1996-01-25 | Hoechst Marion Roussel, Inc. | Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| US6245349B1 (en) * | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| EA001517B1 (ru) * | 1996-06-25 | 2001-04-23 | Глаксо Груп Лимитед | Комбинации, содержащие vx478, зидовудин и 3tc, для применения при лечении вич |
| WO1998007409A1 (en) * | 1996-08-23 | 1998-02-26 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| DE19847618A1 (de) * | 1998-10-15 | 2000-04-20 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US6235782B1 (en) * | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| US6413953B1 (en) * | 1999-04-13 | 2002-07-02 | Anormed Inc. | Pt(IV) antitumor agent |
| HUP0200748A3 (en) * | 1999-04-13 | 2010-01-28 | Anormed Inc | Process for preparing amine platinum complexes |
| GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| WO2001060370A1 (en) * | 2000-02-16 | 2001-08-23 | Yamanouchi Pharmaceutical Co., Ltd. | Remedies for endothelin-induced diseases |
| CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US6545010B2 (en) * | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US20020110601A1 (en) * | 2000-03-31 | 2002-08-15 | Roman Perez-Soler | Antineoplastic platinum therapeutic method and composition |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US6806289B1 (en) * | 2000-07-14 | 2004-10-19 | Stephen J. Lippard | Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same |
| WO2002013817A1 (en) * | 2000-08-11 | 2002-02-21 | Sumitomo Pharmaceuticals Co., Ltd. | Remedies for cisplatin-tolerant cancer |
| US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| CA2326004A1 (en) * | 2000-11-02 | 2002-05-02 | Richard E. Jones | Methods for treating cellular proliferative disorders |
| SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
| AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| US6673370B2 (en) * | 2001-05-15 | 2004-01-06 | Biomedicines, Inc. | Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
| PT1416917E (pt) * | 2001-08-06 | 2007-08-16 | Astrazeneca Ab | ''dispersão aquosa compreendendo nanopartículas estáveis de um triglicérido de cadeia média (mct) activo insolúvel em água e um do tipo excipiente'' |
| WO2003015778A1 (en) * | 2001-08-17 | 2003-02-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
| DE10141528B4 (de) * | 2001-08-24 | 2006-08-10 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung |
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| AU2002353118A1 (en) * | 2001-12-11 | 2003-07-24 | Dor Biopharma, Inc. | Lipid particles and suspensions and uses thereof |
| AU2003220022A1 (en) * | 2002-03-01 | 2003-09-16 | Trustees Of Dartmouth College | Compositions and methods for preventing sporadic neoplasia in colon |
| US20040010553A1 (en) * | 2002-07-15 | 2004-01-15 | International Business Machines Corporation | Peer to peer location based services |
| WO2004006859A2 (en) * | 2002-07-16 | 2004-01-22 | Sonus Pharmaceuticals, Inc. | Platinum compound |
| WO2004012680A2 (en) * | 2002-08-06 | 2004-02-12 | Lyotropic Therapeutics, Inc. | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| US8217010B2 (en) * | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| DE10256182A1 (de) * | 2002-12-02 | 2004-06-24 | Merck Patent Gmbh | 2-Oxadiazolchromonderivate |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| DE502004006542D1 (de) * | 2003-04-30 | 2008-04-30 | Merck Patent Gmbh | Chromenonderivate |
| US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
| WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP2007537235A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療用ピリミジン誘導体 |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TW200600091A (en) * | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| US20080146555A1 (en) * | 2004-06-18 | 2008-06-19 | Gpc Biotech, Inc | Uses of Kinase Inhibitors and Compositions Thereof |
| US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| JP2008513435A (ja) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物 |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| WO2006071812A2 (en) * | 2004-12-23 | 2006-07-06 | H. Lee Moffitt Cancer Center And Research Institute | Platinum iv complex inhibitor |
| US20090047365A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| DK1888550T3 (da) * | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
| US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| WO2007109184A2 (en) * | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| EP2502628B1 (en) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20100297216A1 (en) * | 2006-12-20 | 2010-11-25 | Gabizon Alberto A | Method for administration of pegylated liposomal doxorubicin |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| MX2009008487A (es) * | 2007-02-09 | 2010-01-15 | Poniard Pharmaceuticals Inc | Picoplatino encapsulado. |
| US7687487B2 (en) * | 2007-04-19 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same |
| EP2152076A4 (en) * | 2007-05-31 | 2011-02-16 | Ascenta Therapeutics Inc | PULSATIVE DOSE OF GOSSYPOL FOR THE TREATMENT OF A DISEASE |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
| ES2376175T3 (es) * | 2007-09-28 | 2012-03-09 | Bind Biosciences, Inc. | Direccionamiento a células de c�?ncer usando nanopart�?culas. |
| US20110053879A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
-
2008
- 2008-06-26 TW TW097124033A patent/TW200916094A/zh unknown
- 2008-06-27 CA CA2691115A patent/CA2691115A1/en not_active Abandoned
- 2008-06-27 EP EP08828991.3A patent/EP2157864A4/en not_active Withdrawn
- 2008-06-27 BR BRPI0811816-7A2A patent/BRPI0811816A2/pt not_active IP Right Cessation
- 2008-06-27 JP JP2010514837A patent/JP2010531877A/ja active Pending
- 2008-06-27 CN CN200880022248A patent/CN101801198A/zh active Pending
- 2008-06-27 AU AU2008295576A patent/AU2008295576A1/en not_active Abandoned
- 2008-06-27 KR KR1020107001745A patent/KR20100051797A/ko not_active Withdrawn
- 2008-06-27 WO PCT/US2008/008076 patent/WO2009032034A2/en not_active Ceased
- 2008-06-27 MX MX2009013835A patent/MX2009013835A/es not_active Application Discontinuation
-
2009
- 2009-12-10 US US12/635,534 patent/US20100178328A1/en not_active Abandoned
- 2009-12-10 US US12/635,517 patent/US20100215727A1/en not_active Abandoned
- 2009-12-15 IL IL202743A patent/IL202743A0/en unknown
-
2017
- 2017-03-15 IL IL251175A patent/IL251175A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531877A5 (enExample) | ||
| TW200916094A (en) | Stabilized picoplatin dosage form | |
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| JP2014088444A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| WO2010125462A2 (en) | Pentamidine combinations for treating cancer | |
| ES2537294T3 (es) | Solución de gemcitabina lista para ser infundida | |
| JP2009536956A5 (enExample) | ||
| TW201141473A (en) | Combination therapy for small cell lung cancer | |
| ES2968415T3 (es) | Sistema de perfusión | |
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| WO2024082724A1 (en) | Pim kinase inhibitor in combination with kras inhibitor | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| RU2010102096A (ru) | Стабилизированная лекарственная форма пикоплатина и ее применение | |
| ES3015102T3 (en) | Pharmaceutical composition containing p-boronophenylalanine | |
| WO2011146516A1 (en) | Combination therapy for ovarian cancer | |
| JP2019517490A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
| HK40121309A (en) | Pharmaceutical composition and method for producing same | |
| KR20050116166A (ko) | 이리노테칸의 저항성 유방암 치료용 용도 | |
| CN103127098B (zh) | 一种含有克拉维酸或其盐的抗癌药物组合物及制药用途 | |
| CN118416060A (zh) | 一种新型吴茱萸碱衍生物在制备抗非小细胞肺癌药物中的应用方法 | |
| US20180193335A1 (en) | Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors | |
| Hansen | Micron-sized hydrogel cubes show highly efficient delivery of a potent anti-cancer drug | |
| US20120252829A1 (en) | Tivozanib and capecitabine combination therapy | |
| Wilkes | Drug Essentials: PARP* Inhibitors in BRCA-Associated Cancers |